← All earnings call summaries
Anlon Healthcare Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Expect EBITDA margin normalization to 25-30% range by Q2/Q3 FY27 as raw material prices stabilize
- Capacity expanded to 1400-1600 MT; utilization ~65-70%; new 1200 MT capacity commissioning expected Q1 FY28
- Q1 FY27 consolidated revenue 87.62 Cr (+163% y-y), EBITDA 15.65 Cr, PAT 8.28 Cr
- Consolidated EBITDA margin expected 25-27% for FY27; PAT margin guidance 12-13%
- EBITDA margin moderated to ~17% due to raw material price surge and consolidation of Remember India Health Links
- FY27 revenue guidance raised to 350-400 Cr, driven by organic growth and acquisitions
- Mid-term target: ~30% revenue CAGR over next 3 years with integrated pharma platform
- Working capital days ~170-180; positive operating cash flow expected by FY27 end
📄 Source: View original transcript (PDF)
Get Anlon Healthcare Limited earnings summaries on Telegram
Add Anlon Healthcare Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.